Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy
Updates in Surgery · 2024
DOI: 10.1007/s13304-024-01989-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Updates in Surgery, 2024. Verfasst von Shiyang Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081, Heilongjia…. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Stomach Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, Nomograms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Haiyan Fund, Harbin Medical University Cancer Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The objective is to evaluate whether gastric cancer patients with peritoneal metastasis can benefit from surgery through a comprehensive analysis of different clinical factors and perioperative treatment methods. A total of 135 gastric cancer patients with peritoneal metastasis were treated with Hyperthermic intraperitoneal chemotherapy (HIPEC). Patients were divided into either training group (without surgery, n = 90) or test group (with surgery, n = 45). A nomogram was constructed based on significant prognostic factors. The patients were divided into high- and low-risk groups using a nomogram. Overall survival were then compared according to whether surgery was performed in both groups. Alpha-fetoprotein (AFP), complications, conversion chemotherapy, and postoperative chemotherapy were significantly associated with overall survival ( p < 0.05). A nomogram was constructed using the above four factors and validated using the test set. The area under the curve (AUC) of the model was 0.752 (95% CI 0.525–978). In the group that did not undergo surgery, the median survival times for the high-risk and low-risk groups were 7 and 11 months, respectively. In the surgery group, the median survival times for the high-risk and low-risk groups were 11 and 19 months, respectively. The difference was statistically significant ( p < 0.0001). The four-factor nomogram can accurately predict high-risk and low-risk populations. Our findings suggest that cytoreductive surgery combined with HIPEC can improve the survival time of patients in both groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081, Heilongjiang, China.
- Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Nangang District, Harbin, 150081, Heilongjiang, China. 0696@hrbmu.edu.cn.
Förderung
- Haiyan Fund, Harbin Medical University Cancer Hospital
Zitieren
APA
Jin, S., Wei, Y., Wang, Q., Ju, Y., Wang, Z., Cheng, Q., Li, Z., Liu, X., & Wang, K. (2024). Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy. Updates in Surgery. https://doi.org/10.1007/s13304-024-01989-y
Vancouver
Jin S, Wei Y, Wang Q, Ju Y, Wang Z, Cheng Q, et al. Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy. Updates in Surgery. 2024. doi:10.1007/s13304-024-01989-y
BibTeX
@article{Jin2024,
author = {Jin, Shiyang and Wei, Yuzhe and Wang, Qiancheng and Ju, Yuming and Wang, Zeshen and Cheng, Qingqing and Li, Zhenglong and Liu, Xirui and Wang, Kuan},
title = {Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy},
journal = {Updates in Surgery},
year = {2024},
doi = {10.1007/s13304-024-01989-y}
}
EUVIMED